Deep Iliacus Plane Block Versus Transmuscular Quadratus Lumborum Block for Postoperative Analgesia After Total Hip Arthroplasty

NCT07798830 | Recruiting

• 1 other identifier: 36265PR111/6/26
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to compare the analgesic efficacy, opioid consumption, motor function preservation, and quality of recovery of ultrasound-guided deep iliacus plane block (DIPB) and transmuscular quadratus lumborum block (QLB) in patients undergoing total hip arthroplasty (THA).

Conditions

Deep Iliacus Plane Block; Transmuscular Quadratus Lumborum Block; Postoperative Analgesia; Total Hip Arthroplasty

Outcome Measures

Primary Outcomes (1)

• Degree of pain

  Each patient will be instructed about postoperative pain assessment with VAS. VAS (0 represents "no pain" while 10 represents "the worst pain imaginable"). VAS will be assessed at post-anesthesia care unit (PACU), 2, 4, 6, 12, and 24 h postoperatively.

Secondary Outcomes (5)

• Total morphine consumption

  24 hours postoperatively

• Time to the 1st rescue analgesia

  24 hours postoperatively

• Time for ambulation

  24 hours postoperatively

• Length of hospital stay

  24 hours postoperatively

• Incidence of adverse events

  24 hours postoperatively

Study Arms (2)

Group DIPB

EXPERIMENTAL

Patients will receive ultrasound-guided deep iliacus plane block (DIPB) using 25 mL of 0.25% bupivacaine.

Drug: Deep iliacus plane block

Group QLB

EXPERIMENTAL

Patients will receive ultrasound-guided transmuscular quadratus lumborum block (QLB) using 25 mL of 0.25% bupivacaine.

Drug: Quadratus lumborum block

Interventions

Deep iliacus plane block DRUG

Patients will receive ultrasound-guided deep iliacus plane block (DIPB) using 25 mL of 0.25% bupivacaine.

Group DIPB

Quadratus lumborum block DRUG

Patients will receive ultrasound-guided transmuscular quadratus lumborum block (QLB) using 25 mL of 0.25% bupivacaine.

Group QLB

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years.
• Both sexes.
• American Society of Anesthesiologists (ASA) physical status I-III.
• Scheduled for elective unilateral total hip arthroplasty (THA) under spinal anesthesia.

You may not qualify if:

• Known allergy to local anesthetics or study medications.
• Coagulopathy or anticoagulant therapy contraindicating regional anesthesia.
• Infection at the site of injection.
• Pre-existing neurological deficits affecting the lower limbs.
• Chronic opioid use or opioid dependence.
• Severe hepatic, renal, respiratory, or cardiac disease.
• Body mass index (BMI) \> 40 kg/m².
• Contraindications to spinal anesthesia.

Sponsors & Collaborators

• Tanta University: lead

Study Sites (1)

Tanta University

Tanta, El-Gharbia, 31527, Egypt

RECRUITING

Central Study Contacts

Mohammed S Elsharkawy, MD

CONTACT

00201148207870; mselsharkawy@med.tanta.edu.eg

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.

Study Record Dates

• First Submitted: August 24, 2026
• First Posted: September 1, 2026
• Study Start: September 1, 2026
• Primary Completion (Estimated): March 1, 2027
• Study Completion (Estimated): March 1, 2027
• Last Updated: September 2, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After the end of study for one year.
• Access Criteria: The data will be available upon a reasonable request from the corresponding author.

Locations

EG (1)